IAS 2007: Day Three & Conference Roundup
Joel Gallant, M.D., M.P.H., wraps up our daily recap series with a wide-ranging discussion of important studies on first-line therapy, therapy options for treatment-experienced patients, antiretrovirals in development, abacavir hypersensitivity testing and the metabolic impact of antiretroviral switching.
IAS 2007: Day Two
Daniel Berger, M.D., discusses thought-provoking research on recently approved antiretrovirals and drugs in development, including darunavir, MK-0518 (raltegravir), TMC278 (rilpivirine) and CCR5 inhibitors.
IAS 2007: Day One
Daniel Berger, M.D., recaps early research highlights from the conference, from HIV/hepatitis C coinfection to orally bioavailable fusion inhibitors in development.
CCR5 Entry Inhibitors: Vicriviroc (July 25, 2007)
Edwin DeJesus takes a look at recent data on vicriviroc, a CCR5 entry inhibitor currently being studied in treatment-experienced patients.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Maraviroc Update: An IAS 2007 Summary (July 25, 2007)
Two interesting subanalyses of the maraviroc studies MOTIVATE 1 and 2 show two things: One demonstrates the benefit of including a potent new drug as part of an OBR when initiating treatment in patients with significant resistance. The second subanalysis showed a trend toward higher rates of virologic suppression with twice-daily maraviroc compared to maraviroc once daily. Edwin DeJesus, M.D., reports from IAS.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Faster Viral Decay With Raltegravir (July 24, 2007)
Treatment with raltegravir (RAL, MK-0518) produces more rapid viral load reductions than efavirenz (EFV, Sustiva, Stocrin) and significantly reduced the magnitude of the second phase of viral decay. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Can HLA-B*5701 Testing Help Avoid Abacavir Hypersensitivity Reaction? (July 25, 2007)
Avoiding abacavir hypersensitivity reaction may be as easy as screening for the HLA-B*5701 allele in any HIV-infected, abacavir-naive patient for whom abacavir therapy is being considered. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Tenofovir-Containing Regimens May Not Be the Best Option for Patients With Abnormal Baseline Renal Function (July 25, 2007)
Tenofovir-containing regimens may not be the best option for patients who already have an abnormal baseline renal function; however, for patients with an otherwise normal baseline renal function, who are not taking nephrotoxic agents or who do not have significant comorbid conditions that predispose them to renal insufficiency, routine renal monitoring, as we do for many other patients, should suffice before prescribing tenofovir.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
HIV/TB: An Evolving Epidemic (July 24, 2007)
Available as a Webcast, podcast and transcript.
From kaisernetwork.org
Insight Into the Burden of Coronary Artery Disease in HIV-Infected Patients (July 24, 2007)
This is the first moderately sized study to examine at a histological level the lesions associated with the increased risk of myocardial infarction among HIV-infected individuals that has been reported in multiple case series and cohort studies. Margaret Hoffman-Terry, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
The Role of Nucleoside Analogs in the Development of Insulin Resistance (July 24, 2007)
NRTIs to date have been thought to contribute to insulin resistance mainly via induction of lipoatrophy. The authors of this paper put forth another potential mechanism based on their findings: that is, zidovudine (AZT, Retrovir)-mediated mitochondrial toxicity in skeletal muscle, adipocytes and hepatocytes. Margaret Hoffman-Terry, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Cross-Resistance Between Integrase Inhibitors (July 24, 2007)
It appears that virologic failure with one of the current integrase inhibitors is likely to severely limit subsequent treatment options within that class according to a small cohort study. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
News on HIV Drug Resistance in New Antiretrovirals From the XVI International HIV Drug Resistance Workshop (July 24, 2007)
With every new medication it's critical to understand which mutations are predictive of a less than optimal response. In this report on Doug Richman's review from the XVI International HIV Drug Resistance Workshop, Mark Holodniy, M.D., discusses genotypic and phenotypic assays associated with R5 inhibitors and HIV drug resistance associated with the following antiretrovirals in development: etravirine, raltegravir, elvitegravir and maraviroc.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
First-Line/Second-Line Therapy
ATAZIP: Switching Away From Lopinavir/Ritonavir (July 25, 2007)
Switching from lopinavir/ritonavir (Kaletra) to atazanavir (Reyataz)/ritonavir (Norvir) maintains virologic efficacy and leads to sustained improvements in lipid levels. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Darunavir Matches, and in Some Patients Outperforms, Lopinavir/Ritonavir as Second-Line and Third-Line Treatment (July 25, 2007)
For the first time, a drug has been found that matches the potency of lopinavir/ritonavir in second-line and third-line patients, and which might potentially even outperform lopinavir/ritonavir in certain numbers of those patients. All without compromising safety and tolerability, and apparently without paying resistance consequences if virologic failure occurs. Edwin DeJesus, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Switching to NRTIs Less Associated With Lipoatrophy Is Successful (July 25, 2007)
Since thymidine-sparing, NRTI-based regimens are associated with fewer instances of lipoatrophy and hyperlipidemia than thymidine-containing, NRTI-based regimens, switching to a thymidine-sparing, fixed-dose combination of NRTIs is feasible and associated with no unexpected adverse events, including those affecting renal function and bone mineral density. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
E-Mail
Glossary
Share
